This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

17 Feb 2011

Genus Starts Tumour Drug Trial

Genus Oncology has started its Phase I trial of a treatment for solid tumours.

Genus Oncology has launched its Phase I trial with the first dosage for patient to evaluate GO-203-2c compound which is a treatment for solid tumours.


The prospective, open-label trial is designed to determine the safety, tolerability and potential anti-tumour activity of GO-203-2c.


Up to 40 patients will be enrolled at multiple clinical sites.


GO-203-2c is the optimised lead peptide drug candidate, synthesised to target MUC1, an oncoprotein that is over-expressed in many human carcinomas.


Genus has also filed an investigational new

Related News